NCT05696795View on ClinicalTrials.gov

Janus Kinase Inhibition in Sarcoidosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions

Sarcoidosis

Interventions

DRUG

Abrocitinib 200 mg

Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.

Trial Locations (1)

06510

Yale University, New Haven